Incontinence is common in later life, under-reported, and often treatable without drugs

Urinary incontinence is one of the most common conditions of later life and one of the least discussed, often written off by patients and clinicians alike as an inevitable part of ageing. It is neither inevitable nor untreatable. The first-line treatments with the strongest evidence are not drugs but training — of the pelvic-floor muscles and the bladder — and in stress incontinence, pelvic-floor training cured 56% of women against 6% on no treatment [s1][s2].

This describes what the evidence shows and is not a treatment plan. Incontinence has several types and causes, some signalling other illness, so anyone affected should have it assessed rather than self-manage; the point here is that raising it is worth doing, because effective options exist.

Why it goes unspoken

Incontinence is embarrassing, and embarrassment keeps it hidden. Many older people assume nothing can be done, restrict their lives around it — avoiding trips, outings and exercise — and never mention it to a clinician. That silence has consequences beyond dignity: incontinence, and the night-time waking and rushing it causes, is linked to falls and to earlier moves into residential care. The strongest evidence base is in women, in whom the condition is most studied; incontinence in older men, often related to the prostate, is a distinct problem, though pelvic-floor training also has a role there.

What pelvic-floor training does

The definitive review pooled 31 trials involving 1,817 women across 14 countries, comparing pelvic-floor muscle training with no treatment or an inactive control [s1]. The effects are among the larger ones in this field. For stress incontinence — leakage on coughing, laughing or exertion — women doing pelvic-floor training were eight times more likely to report cure: 56% versus 6% (risk ratio 8.38, 95% confidence interval 3.68 to 19.07; high-quality evidence) [s1]. For any type of incontinence, cure was reported by 35% versus 6% (RR 5.34, 95% CI 2.78 to 10.26) [s1]. Counting improvement as well as cure, 74% of women with stress incontinence improved against 11% of controls, and for any incontinence type 67% improved against 29% (RR 2.39, 95% CI 1.64 to 3.47) [s1]. Women who trained also reported greater improvement in incontinence-specific symptoms and quality of life than untreated controls [s1]. These are training effects, requiring correct technique and persistence, but they are large and well evidenced. The review's main caveats are honest ones: most trials were small, follow-up was generally under 12 months, and the evidence was thinnest for urgency and mixed incontinence, where only single studies were available [s1].

What the guideline recommends

The American College of Physicians translated this evidence into clear, ordered recommendations [s2]. Pelvic-floor muscle training is the first-line treatment for stress incontinence (a strong recommendation on high-quality evidence) [s2]. Bladder training is first-line for urgency incontinence — the sudden, hard-to-defer need to urinate — and the two are combined for mixed incontinence [s2]. For obese women, weight loss and exercise are recommended [s2].

On drugs, the guideline is deliberately restrained. It recommends against systemic drug therapy for stress incontinence, where it does not work well [s2]. For urgency incontinence, it reserves medication for when bladder training has been unsuccessful, and advises choosing agents on tolerability, side effects, ease of use and cost [s2] — a decision that belongs with a clinician, particularly in older adults, in whom some bladder medications carry side effects that matter more with age. The order is the message: behavioural treatment first, drugs second and selectively.

How to read this

The practical takeaways are simple. Incontinence in later life is common and treatable; the treatments with the best evidence are non-drug and can be started with guidance; and medication is a considered second step, not the default. The main barrier to benefit is that the problem is not raised at all. Digital tools are extending access to these behavioural treatments — as in a German trial of a prescribed incontinence app that cut episodes sharply, albeit one built by the product's maker.

What to watch

Most trial evidence is short-term and in women; better data on durability, on men, and on the frailest older adults would strengthen the case. But the core finding — that a condition widely treated as hopeless responds well to training — is robust, and the practical obstacle remains disclosure, not effectiveness.